These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
297 related articles for article (PubMed ID: 18633126)
1. Thoracoabdominal motion in ankylosing spondylitis: association with standardised clinical measures and response to therapy. Tzelepis GE; Kalliakosta G; Tzioufas AG; Sfikakis PP; Mandros C; Boki KA; Roussos C; Moutsopoulos HM Ann Rheum Dis; 2009 Jun; 68(6):966-71. PubMed ID: 18633126 [TBL] [Abstract][Full Text] [Related]
2. Clinimetric evaluation of the bath ankylosing spondylitis metrology index in a controlled trial of pamidronate therapy. Jauregui E; Conner-Spady B; Russell AS; Maksymowych WP J Rheumatol; 2004 Dec; 31(12):2422-8. PubMed ID: 15570645 [TBL] [Abstract][Full Text] [Related]
3. Predictors of treatment response and drug continuation in 842 patients with ankylosing spondylitis treated with anti-tumour necrosis factor: results from 8 years' surveillance in the Danish nationwide DANBIO registry. Glintborg B; Ostergaard M; Krogh NS; Dreyer L; Kristensen HL; Hetland ML Ann Rheum Dis; 2010 Nov; 69(11):2002-8. PubMed ID: 20511613 [TBL] [Abstract][Full Text] [Related]
4. The unmet need for anti-tumour necrosis factor (anti-TNF) therapy in ankylosing spondylitis. Barkham N; Kong KO; Tennant A; Fraser A; Hensor E; Keenan AM; Emery P Rheumatology (Oxford); 2005 Oct; 44(10):1277-81. PubMed ID: 16105913 [TBL] [Abstract][Full Text] [Related]
6. Reference centile charts for measures of disease activity, functional impairment, and metrology in ankylosing spondylitis. Taylor AL; Balakrishnan C; Calin A Arthritis Rheum; 1998 Jun; 41(6):1119-25. PubMed ID: 9627023 [TBL] [Abstract][Full Text] [Related]
7. Prediction of a major clinical response (BASDAI 50) to tumour necrosis factor alpha blockers in ankylosing spondylitis. Rudwaleit M; Listing J; Brandt J; Braun J; Sieper J Ann Rheum Dis; 2004 Jun; 63(6):665-70. PubMed ID: 15037444 [TBL] [Abstract][Full Text] [Related]
8. MRI in predicting a major clinical response to anti-tumour necrosis factor treatment in ankylosing spondylitis. Rudwaleit M; Schwarzlose S; Hilgert ES; Listing J; Braun J; Sieper J Ann Rheum Dis; 2008 Sep; 67(9):1276-81. PubMed ID: 18006539 [TBL] [Abstract][Full Text] [Related]
9. Comparison of the Bath Ankylosing Spondylitis Disease Activity Index and a modified version of the index in assessing disease activity in patients with ankylosing spondylitis without peripheral manifestations. Song IH; Rudwaleit M; Listing J; Sieper J Ann Rheum Dis; 2009 Nov; 68(11):1701-7. PubMed ID: 19029168 [TBL] [Abstract][Full Text] [Related]
10. The platelet functions in patients with ankylosing spondylitis: anti-TNF-alpha therapy decreases the mean platelet volume and platelet mass. Yazici S; Yazici M; Erer B; Erer B; Calik Y; Bulur S; Ozhan H; Ataoglu S Platelets; 2010; 21(2):126-31. PubMed ID: 20050759 [TBL] [Abstract][Full Text] [Related]
11. A six-month randomized, controlled, double-blind, dose-response comparison of intravenous pamidronate (60 mg versus 10 mg) in the treatment of nonsteroidal antiinflammatory drug-refractory ankylosing spondylitis. Maksymowych WP; Jhangri GS; Fitzgerald AA; LeClercq S; Chiu P; Yan A; Skeith KJ; Aaron SL; Homik J; Davis P; Sholter D; Russell AS Arthritis Rheum; 2002 Mar; 46(3):766-73. PubMed ID: 11920413 [TBL] [Abstract][Full Text] [Related]
12. Self- and manual mobilization improves spine mobility in men with ankylosing spondylitis--a randomized study. Widberg K; Karimi H; Hafström I Clin Rehabil; 2009 Jul; 23(7):599-608. PubMed ID: 19403551 [TBL] [Abstract][Full Text] [Related]
13. Persistent clinical efficacy and safety of anti-tumour necrosis factor alpha therapy with infliximab in patients with ankylosing spondylitis over 5 years: evidence for different types of response. Braun J; Baraliakos X; Listing J; Fritz C; Alten R; Burmester G; Krause A; Schewe S; Schneider M; Sörensen H; Zeidler H; Sieper J Ann Rheum Dis; 2008 Mar; 67(3):340-5. PubMed ID: 17967831 [TBL] [Abstract][Full Text] [Related]
14. Changes of clinical response and bone biochemical markers in patients with ankylosing spondylitis taking etanercept. Woo JH; Lee HJ; Sung IH; Kim TH J Rheumatol; 2007 Aug; 34(8):1753-9. PubMed ID: 17610317 [TBL] [Abstract][Full Text] [Related]
15. Trend towards increased arterial stiffness or intima-media thickness in ankylosing spondylitis patients without clinically evident cardiovascular disease. Mathieu S; Joly H; Baron G; Tournadre A; Dubost JJ; Ristori JM; Lusson JR; Soubrier M Rheumatology (Oxford); 2008 Aug; 47(8):1203-7. PubMed ID: 18524805 [TBL] [Abstract][Full Text] [Related]
16. Chest wall motion during speech production in patients with advanced ankylosing spondylitis. Kalliakosta G; Mandros C; Tzelepis GE J Speech Lang Hear Res; 2007 Feb; 50(1):109-18. PubMed ID: 17344552 [TBL] [Abstract][Full Text] [Related]
17. The Swedish version of the Bath ankylosing spondylitis functional index. Reliability and validity. Cronstedt H; Waldner A; Stenström CH Scand J Rheumatol Suppl; 1999; 111():1-9. PubMed ID: 10503553 [TBL] [Abstract][Full Text] [Related]
18. The Swedish version of the Bath ankylosing spondylitis disease activity index. Reliability and validity. Waldner A; Cronstedt H; Stenström CH Scand J Rheumatol Suppl; 1999; 111():10-6. PubMed ID: 10503554 [TBL] [Abstract][Full Text] [Related]
19. Normal thoracoabdominal motions. Influence of sex, age, posture, and breath size. Verschakelen JA; Demedts MG Am J Respir Crit Care Med; 1995 Feb; 151(2 Pt 1):399-405. PubMed ID: 7842198 [TBL] [Abstract][Full Text] [Related]
20. [Clinical study of etanercept for treating ankylosing spondylitis]. Liang LQ; Zhan ZP; Ye YJ; Fu D; Xu HS; Yang XY Nan Fang Yi Ke Da Xue Xue Bao; 2008 Aug; 28(8):1349-51. PubMed ID: 18753057 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]